Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
Running, not enrolling · Phase 2
Conditions studied: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer
In brief
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Key facts
- Study ID
- NCT04736173
- Run by
- Arcus Biosciences, Inc.
- People needed
- 169
- Starts
- 2021-02-08
- Expected to finish
- 2027-05-01
- Last updated by the study team
- 2026-07-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Columbus, Georgia, United States
- Research Site — Kingwood, Texas, United States
- Research Site — Blacksburg, Virginia, United States
- Research Site — Hong Kong, Hong Kong
- Research Site — Johor Bahru, Malaysia
- Research Site — Kuala Lumpur, Malaysia
- Research Site — Kuantan, Malaysia
- Research Site — Kuching, Malaysia
- Research Site — Pulau Pinang, Malaysia
- Research Site — Putrajaya, Malaysia
- Research Site — Mexico City, Mexico
- Research Site — San Luis Potosí City, Mexico
- Research Site — Cebu, Philippines
- Research Site — Davao City, Philippines
- Research Site — Manila, Philippines
- Research Site — Michalovce, Slovakia
- Research Site — George, South Africa
- Research Site — Johannesburg, South Africa
- Research Site — Pretoria, South Africa
- Research Site — Busan, South Korea
- Research Site — Daegu, South Korea
- Research Site — Incheon, South Korea
- Research Site — Jinju, South Korea
- Research Site — Seoul, South Korea
- Research Site — Suwon, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.